US Patent

US9724342 — C-met modulator pharmaceutical compositions

Formulation · Assigned to Exelixis Inc · Expires 2033-07-09 · 7y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical compositions and unit dosage forms containing a compound that modulates C-met.

USPTO Abstract

Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: US9724342
Jurisdiction: US
Classification: Formulation
Expires: 2033-07-09
Drug substance claim: No
Drug product claim: Yes
Assignee: Exelixis Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.